Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
LXRX vs AQST: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
LXRX Captures Overall Composite Edge (48.7 HOLD vs 62.9 BUY), While AQST Leads 3–2 on Growth & Valuation Pillars
LXRX Overall Winner
6-Pillar Tally: LXRX 2 – 3 AQST (1 Tie)
Matrix Metrics: LXRX 4 – 4 AQST
As of Nov 20, 2026, Lexicon Pharmaceuticals, Inc. (LXRX) captures the overall head-to-head institutional edge over Aquestive Therapeutics, Inc. (AQST) on higher Unified Composite conviction (48.7/100 HOLD vs. 62.9/100 BUY) after splitting the core matrix 4–4 (led by Growth & Scale, Options & Positioning), while AQST wins 3–2 across the 6-pillar growth and valuation breakdown. LXRX trades at $1.53 (N/M Forward P/E, -147.4% operating margin) versus AQST at $3.46 (N/M Forward P/E, -114.1% operating margin).
- Composite vs. Pillar Nuance: While AQST currently prints a higher short-term Unified Composite Score (62.9/100 BUY vs. LXRX 48.7/100 HOLD), LXRX captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-147.4% vs. -114.1% operating margin) and revenue trajectory (-20.7% vs. -41.0% YoY).
- Technical & Structure Timing Caution: LXRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.7); meanwhile AQST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About LXRX vs AQST
LXRX
Head-to-Head Winner
Lexicon Pharmaceuticals, Inc.
$1.53
-8.38% 1D
Market Cap
$743.5M
TTM Revenue
$39M
Forward P/E
N/M
Beta / 30D Vol
0.85β · 69% Vol
Unified Composite Score
48.7
HOLD
Tech 25.0
Fund 49.0
Flow 69.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
AQST
Aquestive Therapeutics, Inc. Common Stock
$3.46
-6.61% 1D
Market Cap
$465.7M
TTM Revenue
$49M
Forward P/E
N/M
Beta / 30D Vol
0.89β · 56% Vol
Unified Composite Score
62.9
BUY
Tech 54.0
Fund 68.0
Flow 68.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (LXRX 2 – 3 AQST)
1. Valuation Multiples
AQST
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
19.5x
8.9x
2. Growth & Scale
LXRX
Revenue Growth (YoY)
-20.7%
-41.0%
Earnings Growth (YoY)
-63.4%
+0.0%
TTM Revenue (USD)
$39M
$49M
Market Cap
$743.5M
$465.7M
3. Profitability & Quality
AQST
Gross Margin
91.4%
65.3%
Operating Margin
-147.4%
-114.1%
Net Profit Margin
-161.8%
-162.3%
Return on Equity (ROE)
-43.9%
0.0%
4. Balance Sheet & Cash Flow
AQST
Cash Generation (TTM)
-$49M
-$41M
Cash Flow Margin
N/A
-83.3%
Net Cash / Leverage
$9.5M Net Debt (0.33x D/E)
$32M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
LXRX
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
556.1% (59th %ile)
87.9% (64th %ile)
Put/Call OI Skew
0.13x (Call-Skewed)
0.98x (Balanced)
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Drug Manufacturers - Specialty & Generic Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: LXRX (4) vs AQST (4)| Institutional Metric | LXRX | AQST | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $743.5M | $465.7M | LXRX | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -20.7% | -41.0% | LXRX | |
| Operating Margin (TTM) | -147.4% | -114.1% | AQST | |
| Net Profit Margin | -161.8% | -162.3% | LXRX | |
| Return on Equity (ROE) | -43.9% | 0.0% | AQST | |
| 52-Week Range Position | 27% ($1–$3) | 14% ($3–$7) | LXRX | |
| Beta / 30D Volatility | 0.85β · 69% Vol | 0.89β · 56% Vol | AQST | |
| Unified Institutional Score | 48.7 / 100 (HOLD) | 62.9 / 100 (BUY) | AQST | |
| Trailing 12M Revenue (USD) | $39M | $49M | Scale | |
| Gross Profit Margin (TTM) | 91.4% | 65.3% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 19.5x EV/Rev | N/M PEG · 8.9x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$49M ($9.5M Net Debt (0.33x D/E)) | -$41M ($32M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
LXRX +18.9 pp
3M Horizon
AQST +6.13 pp
6M Horizon
AQST +13.15 pp
1Y Horizon
LXRX +46.17 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | LXRX Revenue | AQST Revenue | LXRX Op. Margin | AQST Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $30M | $70M | -388.5% | -72.6% | AQST |
| FY2019 | $30M | $50M | 437.5% | -100.1% | LXRX |
| FY2020 | $20M | $50M | -204.2% | -93.6% | AQST |
| FY2021 | N/A | $50M | N/A | -68.2% | AQST |
| FY2022 | N/A | $50M | N/A | -88.2% | AQST |
| FY2023 | $0M | $50M | -15473.0% | -29.9% | AQST |
| FY2024 | $10M | $60M | -3284.7% | -53.5% | AQST |
| FY2025 | $50M | $40M | -98.2% | -159.5% | LXRX |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
LXRX
BREAKDOWN
Current IV
556.1%
IV Percentile
59th %ile
Put/Call OI Skew
0.13x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact LXRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
AQST
BREAKDOWN
Current IV
87.9%
IV Percentile
64th %ile
Put/Call OI Skew
0.98x (Balanced)
IV Regime
Elevated (60th–80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact AQST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
LXRX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
AQST Moat Profile
Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ LXRX vs AQST Key Questions & Quantitative Answers
As of Nov 20, 2026, Lexicon Pharmaceuticals, Inc. (LXRX) captures the overall head-to-head institutional edge over Aquestive Therapeutics, Inc. (AQST) on higher Unified Composite conviction (48.7/100 HOLD vs. 62.9/100 BUY) after splitting the core matrix 4–4 (led by Growth & Scale, Options & Positioning), while AQST wins 3–2 across the 6-pillar growth and valuation breakdown. LXRX trades at $1.53 (N/M Forward P/E, -147.4% operating margin) versus AQST at $3.46 (N/M Forward P/E, -114.1% operating margin). Composite vs. Pillar Nuance: While AQST currently prints a higher short-term Unified Composite Score (62.9/100 BUY vs. LXRX 48.7/100 HOLD), LXRX captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-147.4% vs. -114.1% operating margin) and revenue trajectory (-20.7% vs. -41.0% YoY). Technical & Structure Timing Caution: LXRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.7); meanwhile AQST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
LXRX leads the Growth & Scale pillar: LXRX posts -20.7% YoY revenue growth and -63.4% YoY earnings growth on $39M TTM revenue (91.4% gross margin, -147.4% operating margin), compared with AQST at -41.0% YoY revenue growth and +0.0% YoY earnings growth on $49M TTM revenue (65.3% gross margin, -114.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), LXRX cumulative revenue shifted +66.7% while AQST shifted -42.9%. In operating R&D and SG&A reinvestment, LXRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AQST.
AQST screens cheaper on headline valuation multiples. LXRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 19.5x EV/Revenue (unreported FCF margin), whereas AQST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.9x EV/Revenue (-83.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LXRX (-43.9% ROE) versus AQST (0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, LXRX carries 556.1% implied volatility (59th %ile, Balanced (25th–60th %ile)), a 0.13x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.85β · 69% Vol realized risk). By comparison, AQST carries 87.9% implied volatility (64th %ile, Elevated (60th–80th %ile)), a 0.98x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 56% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
AQST vs LXRX · Reverse Pair
LXRX vs RIGL
· Sector Peer
LXRX vs AGEN
· Sector Peer
LXRX vs EXEL
· Sector Peer
AQST vs SVRA
· Sector Peer
AQST vs ETON
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem